tetano
Editor, Senior Moderator
J Neurovirol
. 2020 Jul 27.
doi: 10.1007/s13365-020-00884-7. Online ahead of print.
Severe rapidly progressive Guillain-Barr? syndrome in the setting of acute COVID-19 disease
Rory M C Abrams[SUP] 1 [/SUP], Brian D Kim[SUP] 2 [/SUP], Desiree M Markantone[SUP] 2 [/SUP], Kaitlin Reilly[SUP] 3 [/SUP], Alberto E Paniz-Mondolfi[SUP] 4 [/SUP], Melissa R Gitman[SUP] 4 [/SUP], S Yoon Choo[SUP] 4 [/SUP], Winona Tse[SUP] 5 [/SUP], Jessica Robinson-Papp[SUP] 6 [/SUP]
Affiliations
Abstract
There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barr? syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
Keywords: Coronavirus-19; Guillain-Barr? syndrome; Neuromuscular disorders; Polyneuropathy; SARS-CoV-2.
. 2020 Jul 27.
doi: 10.1007/s13365-020-00884-7. Online ahead of print.
Severe rapidly progressive Guillain-Barr? syndrome in the setting of acute COVID-19 disease
Rory M C Abrams[SUP] 1 [/SUP], Brian D Kim[SUP] 2 [/SUP], Desiree M Markantone[SUP] 2 [/SUP], Kaitlin Reilly[SUP] 3 [/SUP], Alberto E Paniz-Mondolfi[SUP] 4 [/SUP], Melissa R Gitman[SUP] 4 [/SUP], S Yoon Choo[SUP] 4 [/SUP], Winona Tse[SUP] 5 [/SUP], Jessica Robinson-Papp[SUP] 6 [/SUP]
Affiliations
- PMID: 32720233
- DOI: 10.1007/s13365-020-00884-7
Abstract
There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barr? syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.
Keywords: Coronavirus-19; Guillain-Barr? syndrome; Neuromuscular disorders; Polyneuropathy; SARS-CoV-2.